PMCB (PharmaCyte Biotech) Other Current Assets : $0.21 Mil (As of Jan. 2025)

PharmaCyte Biotech Other Current Assets Chart

PharmaCyte Biotech Annual Data
	Trend	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23	Apr24
Other Current Assets		Get a 7-Day Free Trial					0.14	0.07	0.09	0.11	0.26

PharmaCyte Biotech Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Other Current Assets	Get a 7-Day Free Trial															0.30	0.26	0.24	0.49	0.21

PharmaCyte Biotech Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:

The assets grouped under other current assets are most commonly:

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

PharmaCyte Biotech Other Current Assets Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCyte Biotech Business Description